What does business segments — collaboration loss mean?

This metric captures the financial losses recognized from shared research, development, or commercialization agreements with external partners. It reflects the company's portion of costs or negative outcomes associated with joint ventures in the oncology space. Investors use this to evaluate the financial impact of strategic partnerships on the bottom line.

Syndax Pharmaceuticals SNDX Business Segments — Collaboration Loss

Similar metrics at other companies

REGNCollaboration revenue — Revenue

$1.9B+24.1%

NRIXCollaboration revenue — Revenue

$6.25M-66.1%

BIIBCollaboration profit sharing/(loss reimbursement)

$72.55M+14.1%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

ALMSCollaboration Revenue — Revenue

$1.74M—

EXELCollaboration — Total revenues

$55.84M+32.4%

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.77B+95.0%

Enterprise value$1.99B+84.0%

P/S8.1×-12.6×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept sndx:CollaborationLoss.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's business segments — collaboration loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's business segments — collaboration loss?: Syndax Pharmaceuticals (SNDX) reported business segments — collaboration loss of $0 in Q1 2026.
What does business segments — collaboration loss mean?: This metric captures the financial losses recognized from shared research, development, or commercialization agreements with external partners. It reflects the company's portion of costs or negative outcomes associated with joint ventures in the oncology space. Investors use this to evaluate the financial impact of strategic partnerships on the bottom line.